Valuation: Axsome Therapeutics, Inc.

Market Cap 11.19B 9.68B 9.1B 8.27B 15.53B 1,068B 15.8B 107B 41.64B 535B 42B 41.11B 1,784B P/E 2026 *
-80.2x
P/E 2027 * 45.8x
Enterprise Value 11.04B 9.54B 8.97B 8.16B 15.31B 1,053B 15.58B 105B 41.05B 528B 41.42B 40.53B 1,759B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 6.89x
Free-Float
84.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
1 week+0.30%
Current month-2.12%
1 month-10.17%
3 months-6.30%
6 months+17.75%
Current year+16.83%
1 week 208.95
Extreme 208.95
223.4
1 month 206.94
Extreme 206.94
245.5
Current year 152.28
Extreme 152.28
260.19
1 year 109.4
Extreme 109.4
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

13,980 0.0272%
01/07/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
05/06/26 Free

Director

1,721 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%+0.30%+95.37%+199.01% 11.19B
-0.31%+2.44%+38.43%-0.30% 80.23B
-1.02%-0.51%-2.54%+26.80% 50.64B
-3.10%-4.84%+10.29%+158.34% 46.87B
-0.74%+3.26%-49.51%-49.96% 46.34B
-0.39%+0.91%+51.39%-22.35% 31B
-0.52%+7.01%+125.98%-34.32% 25.28B
-0.30%-0.33%+38.24%+83.70% 24.36B
-1.42%-1.11%-3.79%+190.40% 20.81B
-1.83%-2.82%+60.85%+107.54% 16.08B
Average -0.98%+1.47%+36.47%+65.89% 35.28B
Weighted average by Cap. -0.99%+1.15%+25.00%+42.05%

Financials

2026 *2027 *
Net sales 971M 840M 790M 718M 1.35B 92.65B 1.37B 9.24B 3.61B 46.44B 3.64B 3.57B 155B 1.56B 1.35B 1.27B 1.15B 2.17B 149B 2.21B 14.87B 5.81B 74.71B 5.86B 5.74B 249B
Net income -140M -121M -114M -103M -194M -13.32B -197M -1.33B -519M -6.68B -524M -513M -22.25B 259M 224M 210M 191M 359M 24.69B 365M 2.46B 962M 12.37B 971M 950M 41.23B
Net Debt -156M -135M -127M -116M -217M -14.93B -221M -1.49B -582M -7.48B -587M -575M -24.94B -435M -376M -354M -322M -604M -41.54B -615M -4.14B -1.62B -20.82B -1.63B -1.6B -69.38B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
14/08/26 US$213.67 -0.00% 476,327
13/08/26 US$213.68 -0.46% 705,315
12/08/26 US$214.66 -0.51% 1,240,601
11/08/26 US$215.77 -2.32% 834,377
10/08/26 US$220.89 +3.83% 1,398,625
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
213.67USD
Average target price
285.42USD
Spread / Average Target
+33.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock